SecBot SecBot
8-K ·Filed Jul 16, 2026

ABT

ABBOTT LABORATORIES
BULLISH
Impact 6/10
Horizondays Processed4mo ago SEC0001628280-26-048377
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The EPS beat and raised guidance are modest positives, but the $385M legal reserve and GAAP earnings decline warrant caution. Monitor the legal settlement outcome and Nutrition segment recovery for sustained momentum. The raised EPS guidance suggests management confidence in H2 acceleration.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$98.83
T+0 close · Jul 16, 2026 · via day close
Latest settled
+0.78%
T+60 · $99.60
Vs SPY
−2.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 16 $98.83entry
  2. T+1 · 4mo ago +1.87%α +2.86% · $100.68
  3. T+5 · 4mo ago +1.94%α +3.61% · $100.75
  4. T+20 · 3mo ago +12.59%α +8.97% · $111.27
  5. T+60 · 6w ago +0.78%α −2.93% · $99.60
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Abbott reported Q2 2026 adjusted diluted EPS of $1.31, a 2.6% beat vs. consensus of $1.28, on reported sales of $12.593B (vs. $12.52B consensus). Comparable sales grew 4.8% YoY. The company raised its full-year 2026 adjusted EPS guidance to $5.45-$5.60 from $5.38-$5.58, while reaffirming comparable sales growth of 6.5%-7.5%. GAAP EPS was $0.53, depressed by $1.362B in specified items including $385M in legal reserves and $658M in intangible amortization.

Key Financial Metrics

EPS
$1.31
est $1.28 · +2.3%
Revenue
$12.6B
est $12.5B · +0.6% · +13.0% YoY
Rating
beat
Guidance
6.5%-7.5% comparable sales growth
raised

Key Facts

  • Adjusted diluted EPS of $1.31 beat consensus of $1.28 by 2.6%
  • Reported sales of $12.593B vs. consensus of $12.52B, up 13.0% reported / 4.8% comparable YoY
  • Full-year 2026 adjusted EPS guidance raised to $5.45-$5.60 from $5.38-$5.58
  • Full-year 2026 comparable sales growth guidance reaffirmed at 6.5%-7.5%
  • GAAP EPS was $0.53, impacted by $1.362B in specified items including $385M legal reserve
  • Medical Devices comparable sales grew 8.4% YoY; Diabetes Care CGM sales grew 9.5% comparable
  • Cancer Diagnostics (Exact Sciences) comparable sales grew 13.3% YoY
  • Returned $2.1B to shareholders via dividends and share repurchases in Q2

Financial Impact

Adjusted EPS beat by ~$0.03; guidance raised by $0.07 at midpoint; $2.1B returned to shareholders

epsrevenueguidance

Risk Factors

  • Nutrition segment continues to decline (-3.6% comparable YoY) due to pricing actions and volume weakness
  • GAAP operating earnings fell 17.5% YoY due to acquisition-related costs and legal reserves
  • Exact Sciences integration costs and $385M legal reserve create earnings noise
  • Rapid/Molecular Diagnostics declining (-8.0% comparable) due to weaker respiratory season

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-048377
Document: abt-20260716.htm0001628280-26-048377
Document: 0001628280-26-048377-index-headers.html0001628280-26-048377
Document: 0001628280-26-048377-index.html0001628280-26-048377
Document: 0001628280-26-048377.txt0001628280-26-048377
8-K Data (Synthetic)0001628280-26-048377

Track record

38 reports on ABT

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +17.16% at T+20 after the Jul 1, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 5, 202611d ago 144 Neutral 2/10 Entry $109.93 Now $108.52 −1.28% settles Dec 7
  2. Oct 27, 202620d ago ANALYST-DOWNGRADE Neutral 2/10 Entry $103.10 Now $108.52 +5.26% settles Nov 24
  3. Oct 27, 202621d ago Court Ruling Neutral 1/10 Entry $102.64 Now $108.52 +5.73% settles Nov 25
  4. Oct 21, 202626d ago Institutional Cluster Mixed 4/10 Entry $102.51 Now $108.52 +5.86% settles Nov 19
  5. Oct 21, 202626d ago 8-K Bullish 6/10 Entry $100.51 Now $108.52 +7.97% settles Nov 18
  6. Oct 21, 202626d ago 8-K Bearish 6/10 No price data
  7. Oct 21, 202626d ago Press Release Neutral 4/10 Entry $100.51 Now $108.52 +7.97% settles Nov 18
  8. Oct 20, 202628d ago Court Ruling Neutral 1/10 Entry $100.51 Now $108.52 +7.97% settles Nov 18
  9. Oct 16, 20264w ago Court Ruling Neutral 2/10 Entry $104.06 to $107.45 Now $108.52 +4.29% ▲ +3.26% +6.72% vs SPY
  10. Oct 15, 20264w ago Court Ruling Bullish 5/10 Entry $104.89 to $108.52 Now $108.52 +3.46% ▲ +3.46% +4.62% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (11h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 16, 2026